Effectiveness of Lobeline in Treating Symptoms of ADHD in Adult Patients

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Yaupon Therapeutics
ClinicalTrials.gov Identifier:
NCT00664703
First received: April 21, 2008
Last updated: June 19, 2013
Last verified: June 2013
  Purpose

The study will evaluate the effectiveness of the nonstimulant medication lobeline in improving symptoms of attention deficit hyperactivity disorder in adults.


Condition Intervention Phase
Attention Deficit Disorder With Hyperactivity
Drug: Lobeline sulfate
Drug: Methylphenidate HCl
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients

Resource links provided by NLM:


Further study details as provided by Yaupon Therapeutics:

Primary Outcome Measures:
  • Attention as measured by Conners' Continuous Performance Task(CPT) [ Time Frame: Measured at Lab Visits 1 through 7 ] [ Designated as safety issue: No ]
  • Impulsivity as measured by the CPT and Stop Signal Reaction Test [ Time Frame: Measured at Lab Visits 1 through 7 ] [ Designated as safety issue: No ]
  • Working memory as measured by Digit Span Backwards and Two-Back Test [ Time Frame: Measured at Lab Visits 1 through 7 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Subjective effects [ Time Frame: Measured at Lab Visits 1 through 7 ] [ Designated as safety issue: No ]
  • Cardiovascular effects [ Time Frame: Measured at Lab Visits 1 through 7 ] [ Designated as safety issue: Yes ]
  • Drug effects [ Time Frame: Measured at Lab Visits 1 through 7 ] [ Designated as safety issue: No ]

Enrollment: 13
Study Start Date: July 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lobeline 7.5 mg
Sublingual tablet
Drug: Lobeline sulfate
Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Experimental: Lobeline 15 mg
Sublingual tablet
Drug: Lobeline sulfate
Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Experimental: Lobeline 30 mg
Sublingual tablet
Drug: Lobeline sulfate
Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Active Comparator: Methylphenidate HCl 15 mg
Capsule
Drug: Methylphenidate HCl
Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Active Comparator: Methylphenidate HCl 30 mg
Capsule
Drug: Methylphenidate HCl
Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Placebo Comparator: Lobeline 0 mg (placebo)
Sublingual tablet
Drug: Placebo
Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Placebo Comparator: Methylphenidate HCl 0 mg (placebo)
Capsule
Drug: Placebo
Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

Detailed Description:

Attention deficit hyperactivity disorder (ADHD) affects approximately 8 million adults in the United States. Adults with ADHD may experience difficulty concentrating, poor organization ability, mood swings, and trouble completing work. If not managed properly, ADHD can lead to behavioral, emotional, academic, social, and work-related problems. Neurobiological research has shown that people with ADHD exhibit low levels of dopamine, a neurotransmitter of the brain that controls a person's ability to concentrate and focus on surroundings. Lobeline, a nonstimulant medication that acts to alter dopamine uptake, may be effective in improving abnormalities in brain dopamine levels. Although lobeline has been successfully used as a smoking cessation aid because of its ability to inhibit nicotine-induced hyperactivity, the effectiveness of lobeline as a treatment for ADHD has not been explored. This study will evaluate the effectiveness of lobeline in improving adult ADHD symptoms, specifically inattention, impulsivity, and memory problems. This study will also evaluate any side effects of lobeline treatment.

Participation in this study will last between 4 and 5 weeks, during which participants will attend 10 study visits at the General Clinical Research Center (GCRC). Participants will first undergo a medical evaluation visit that will include a physical exam, electrocardiogram (EKG), blood draw, urine testing, and breath sampling. Participants will then return for an orientation visit to complete questionnaires and to receive training on the computer and on memory tasks to be performed during later visits.

The next 7 visits will comprise the laboratory testing and medication treatment portion of the study. Each visit will last 4.5 hours and will include urine and breath sampling, computer and memory tasks, questionnaires, vital sign measurements, and medication distribution. Participants will be randomly assigned to take two different pills at each lab visit. One pill will be a placebo of lobeline or methylphenidate, a medication stimulant used in treating ADHD, and the other pill will be active lobeline or methylphenidate. Drug combinations and doses will vary each day, but participants will never receive two active pills on the same day. All participants will undergo a follow-up evaluation between 7 and 14 days after the final lab visit. The evaluation will include questions about side effects from study medication, breath and urine sampling, a blood draw, and a physical exam.

  Eligibility

Ages Eligible for Study:   21 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of ADHD, including degree of symptomatology, as determined by a structured clinical assessment based on the DSM-IV (SCID-1); supplemented by administration of the Schedule for Affective Disorders and Schizophrenia for School-Age Children, Epidemiologic version (KSADS-E) and administration of the Conners' Adult ADHD Rating Scale (CAARS);
  • Healthy males or females aged 21 to 45 years;
  • A body mass index (BMI) between 18 and 30;
  • Ability and willingness to provide written consent, comply with study instructions, and commit to all study visits and procedures;
  • Adequate means of contacting the investigator in case of emergency or have means to be contacted readily by the investigator;
  • No medical contraindications determined by the following: an adequate medical history, a physical examination including vital signs, 12-lead electrocardiogram (ECG); complete blood count with differential liver function and blood chemistry tests and urinalysis, including urine sample for drug screening;
  • A negative urine drug test (barbiturates, benzodiazepines, amphetamines, opiates, cocaine, cannabinoids, ethanol) at screening, and at each laboratory day;
  • Subjects must be non-smokers. A breath sample analysis will be conducted on-site with an Alco-Sensor Intoximeter, and an Innovative Medical Monitoring carbon monoxide (CO) Monitor, and must reveal a CO value of less than or equal to 8 ppm and a negative cotinine urine or saliva test (>100 ng/mL);
  • Females must have a negative pregnancy test (beta human chorionic gonadotrophin) at screening, and prior to each study drug administration. Females capable of childbearing are required to use a medically accepted form of contraception for at least 1 month prior to study start, throughout the study duration, and for at least 1 month after study medication is discontinued.

Exclusion Criteria:

  • Current participation in the follow-up period of a preceding drug research study;
  • Presence of unresolved/unstable psychiatric comorbidities as determined by clinical assessment and structured clinical interview using the SCID-1, that could interfere with study evaluations or affect a subject's safety;
  • Recent history of drug addiction and/or alcoholism; and nicotine dependence within the past 6 months, as determined by psychiatric clinical assessment;
  • Current significant acute or chronic medical disease, or any historical medical condition that could relapse during or immediately after the study and, in the investigator's opinion, may interfere with study evaluations or affect a subject's safety;
  • Presence of potential organic etiology (e.g., a serious head injury or injury resulting in loss of consciousness, seizure disorder, thyroid problems, etc.) for ADHD symptomatology, as determined by clinical assessment;
  • Blood pressure over 160/100 mmHg or under 90/40 mmHg, or heart rate over 120 beats per minute or below 40 beats per minute, obtained on two consecutive measures over 15 minutes when the subject is at rest;
  • Exposure to any investigational new drug within 30 days of screening;
  • Regular use of any prescription, over-the-counter drugs or likely need for concomitant treatment medication during the study period;
  • Use of herbal products, including St. John's Wort, for 2 weeks prior to study initiation and throughout the study duration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00664703

Locations
United States, Kentucky
General Clinical Research Center, University of Kentucky
Lexington, Kentucky, United States, 40506
Sponsors and Collaborators
Yaupon Therapeutics
Investigators
Principal Investigator: Catherine A. Martin, MD University of Kentucky Department of Psychiatry
  More Information

No publications provided

Responsible Party: Yaupon Therapeutics
ClinicalTrials.gov Identifier: NCT00664703     History of Changes
Other Study ID Numbers: R43 MH081553, R43MH081553, DATR BT-BU, 2007LOBADHD-201-US, 7-0432-F2L
Study First Received: April 21, 2008
Last Updated: June 19, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Yaupon Therapeutics:
Dopamine Uptake Inhibitors
Dopamine
Methylphenidate
Mental Disorders Diagnosed in Childhood
Neurologic Manifestations
Attention Deficit and Disruptive Behavior Disorders
Hyperkinesis
Dyskinesias

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Lobeline
Methylphenidate
Dopamine Uptake Inhibitors
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Respiratory System Agents
Therapeutic Uses
Central Nervous System Stimulants
Central Nervous System Agents
Dopamine Agents
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on August 28, 2014